WRG-28 NEW
| Price | $40 | $89 | $147 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: WRG-28 | CAS No.: 1913291-02-7 |
| Purity: 97.84% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | WRG-28 |
| Description | WRG-28 is a potent and selective, allosteric discoidin domain receptor 2 (ddr2) inhibitor(IC50 : 230 nM) |
| In vitro | WRG-28 is a selective, extracellularly acting small molecule inhibitor of DDR2 that uniquely inhibits receptor-ligand interactions via allosteric modulation of the receptor.?By targeting DDR2, WRG-28 inhibits tumor invasion and migration, as well as tumor-supporting roles of the stroma, and inhibits metastatic breast tumor cell colonization in the lungs. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.44 mM), Sonication is recommended. DMSO : 15 mg/mL (36.55 mM), Sonication is recommended. |
| Keywords | WRG-28 | WRG28 | WRG 28 | rheumatoid arthritis | joint destruction | Inhibitor | inhibit | HEK293 | DiscoidinDomainReceptor(DDR) | DiscoidinDomainReceptor | Discoidin Domain Receptor (DDR) | Discoidin Domain Receptor | DDR2 | DDR | CAFs | BT549 | breast cancer | 4T1 breast cancer cells |
| Inhibitors Related | DDR-TRK-1 | DDR Inhibitor | VU6015929 | Ddr1-In-1 | DDR1-IN-4 | FGFR1/DDR2 inhibitor 1 | Sitravatinib | LCB 03-0110 | Merestinib | DDR1-IN-2 | GLPG3312 | (S)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $65.00 |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2026-05-05 | |
| $10.00 |
VIP4Y
|
GIHI CHEMICALS CO.,LIMITED
|
2026-04-16 | |
| $1520.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY